Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 1Q Financial Report: Schering-Plough | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

1Q Financial Report: Schering-Plough

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough

1Q Revenues: $2.6 billion (+8%)

1Q Earnings: $350 million (earnings were $105 million in 1Q2005)

Comments: The sales increase for the quarter was driven by Remicade, Nasonex, Temodar and Peg-Intron. Remicade sales were up 26% to $278 million, Temodar sales grew 25% to $163 million, Nasonex sales were up 25% to $229 million. Global sales of Peg-Intron were up 16% to $196 million in the quarter. R&D spending for the quarter totaled $481 million, up 25%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters